Semaglutide News and Research

Latest Semaglutide News and Research

Study points to a surprising new ally in the fight against type 2 diabetes

A new study from Duke University School of Medicine is challenging long-standing views on blood sugar regulation - and pointing to a surprising new ally in the fight against type 2 diabetes.

19 Sep 2025

Can eating style affect how well GLP-1 drugs control diabetes and weight?

Research indicates that external eating behavior is a key predictor of weight loss in type 2 diabetes patients receiving GLP-1 receptor agonists.

19 Sep 2025

Closed Loop Medicine launches first personalized GLP-1 dosing platform In U.S.

Closed Loop Medicine Ltd (CLM), a leader in personalized pharmaceutical dosing, today announced the U.S. launch of WeDosify, which enables clinicians to personalize GLP-1 titration at scale.

19 Sep 2025

Oral GLP-1 drug orforglipron achieves significant weight loss in global trial

Patients taking an experimental oral GLP-1 drug lost significant weight and improved their heart and metabolic risk factors in a large, international, phase III clinical trial led by investigators at Weill Cornell Medicine, McMaster University, York University and other institutions

18 Sep 2025

New trial demonstrates efficacy of tirzepatide in children and adolescents with type 2 diabetes

New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both.

18 Sep 2025

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

In a phase 3 trial, once-daily oral orforglipron induced significant, dose-dependent weight loss over 72 weeks in adults with obesity but no diabetes. It also improved multiple cardiometabolic markers with a safety profile similar to other GLP-1 receptor agonists.

18 Sep 2025

Scientists unveil new obesity drug that reprograms fat and energy use

Details of a new drug that aims to treat the underlying causes of obesity are being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September).

18 Sep 2025

GLP-1RAs linked to lower risk of mortality and cardiovascular events in psoriasis patients

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% lower risk of major cardiovascular events compared to those taking other diabetes or weight-loss medications, new research has shown.

17 Sep 2025

New genetic test can help predict how people will respond to weight-loss medications

Mayo Clinic researchers have developed a genetic test that can help predict how people will respond to weight loss medications such as GLP-1s.

17 Sep 2025

A new tool in the fight against obesity: Orforglipron's substantial weight loss results

New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15-19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living with obesity that do not have type 2 diabetes.

17 Sep 2025

GLP-1 drugs found to protect against diabetic retinopathy

GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss, suggests new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published in the journal Pharmaceutics.

17 Sep 2025

The mind-gut connection: How emotional eating affects GLP-1 drug success

GLP-1 receptor agonists like Ozempic can be a lifeline for people with diabetes - helping stabilize blood glucose and lose weight which contributes to diabetes complications. But not everyone benefits equally.

17 Sep 2025

Exercise found to reduce artery hardening after weight loss in adults with obesity

Maintaining weight loss with regular exercise rather than the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide, a drug used to treat type 2 diabetes and obesity, seems to reduce atherosclerosis development in adults with obesity-a leading underlying cause of cardiovascular disease.

17 Sep 2025

Can changing food texture reduce how much we eat? Dutch study investigates

A new randomized controlled trial protocol from the Netherlands will test whether altering the texture, and thus the eating rate, of ultra-processed foods can reduce daily energy intake. The study will investigate how sensory properties, such as food hardness, affect metabolism, appetite, and microbiome composition.

16 Sep 2025

Higher-dose semaglutide helps people lose nearly 19% of body weight

The STEP UP trial reveals semaglutide 7.2 mg significantly reduces weight compared to 2.4 mg, though it raises questions about gastrointestinal side effects.

16 Sep 2025

Cleveland Clinic study shows lasting benefits of weight-loss surgery over GLP-1 medicines

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo weight-loss surgery live longer and face fewer serious health problems compared with those treated with GLP-1 receptor agonist medicines alone.

16 Sep 2025

Individuals taking semaglutide for weight loss experience less food noise than before

New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) shows that individuals who are taking semaglutide for weight loss experience less food noise than before.

16 Sep 2025

GLP-1 drugs may offer cost-effective treatment for people with knee osteoarthritis and obesity

A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for people with knee osteoarthritis and obesity, with tirzepatide providing greater health benefits at lower cost compared to semaglutide.

16 Sep 2025

Study: Half of adults without diabetes taking weight-loss drug discontinue treatment within a year

The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at helping individuals lose weight.

15 Sep 2025

Are GLP-1 drugs safe for women planning pregnancy?

A study reveals rising GLP-1 prescriptions in young women, highlighting low contraception use and potential risks for unintended pregnancies and fetal outcomes.

12 Sep 2025

Semaglutide News and Research

Latest Semaglutide News and Research

Study points to a surprising new ally in the fight against type 2 diabetes

Can eating style affect how well GLP-1 drugs control diabetes and weight?

Closed Loop Medicine launches first personalized GLP-1 dosing platform In U.S.

Oral GLP-1 drug orforglipron achieves significant weight loss in global trial

New trial demonstrates efficacy of tirzepatide in children and adolescents with type 2 diabetes

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

Scientists unveil new obesity drug that reprograms fat and energy use

GLP-1RAs linked to lower risk of mortality and cardiovascular events in psoriasis patients

New genetic test can help predict how people will respond to weight-loss medications

A new tool in the fight against obesity: Orforglipron's substantial weight loss results

GLP-1 drugs found to protect against diabetic retinopathy

The mind-gut connection: How emotional eating affects GLP-1 drug success

Exercise found to reduce artery hardening after weight loss in adults with obesity

Can changing food texture reduce how much we eat? Dutch study investigates

Higher-dose semaglutide helps people lose nearly 19% of body weight

Cleveland Clinic study shows lasting benefits of weight-loss surgery over GLP-1 medicines

Individuals taking semaglutide for weight loss experience less food noise than before

GLP-1 drugs may offer cost-effective treatment for people with knee osteoarthritis and obesity

Study: Half of adults without diabetes taking weight-loss drug discontinue treatment within a year

Are GLP-1 drugs safe for women planning pregnancy?

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Semaglutide News and Research

Latest Semaglutide News and Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in